YDYuanyuan Dai

Yuanyuan Dai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanyuan Dai has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoling Ma

    Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    2 shared publications
  • Bing Lu

    University of Science and Technology of China

    1 shared publication
  • Chenggong Guo

    University of Science and Technology of China

    1 shared publication
  • Gan Liu

    University of Science and Technology of China

    1 shared publication
  • Gan Liu

    Department of Clinical Laboratory, Division of Life Sciences and Medicine, The First Affiliated Hospital of University of Science and Technology of China (USTC), Anhui, China

    1 shared publication
  • Gang Wu

    Department of Research and Development, Precision Diagnostic Inc, Anhui, China

    1 shared publication

Latest Publications

  • Vancomycin-stressed Staphylococcus aureus extracellular vesicles hijack macrophage autophagy to enhance bacterial intracellular survival

    by Bing Lu, Wenjiao Chang, Xueer Liu, Shanshan Zhang, Pengsheng Ding, Zhengchao Nie, Lan Shi, Gan Liu, Wenjin Wang, Yujie Wei, et al.

    Staphylococcus aureus infections, notably those involving MRSA, are clinically common and pose a persistent therapeutic challenge [1,2]. Vancomycin, a glycopeptide antibiotic, has long been the cor...


  • Open Access

    ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway

    by Shanshan Zhang, Gang Wu, Lan Shi, Pengsheng Ding, Gan Liu, Wenjiao Chang, Yuanyuan Dai, Xinghua Han, Xiaoling Ma

    Background: Epigenetic dysregulation constitutes one of the mechanisms in the pathogenesis of HCC, thereby underscoring its critical scientific importance for early diagnosis and therapeutic interventions. The chromatin remodeling factor AT-rich interaction domain 1A (ARID1A) serves as an essential epigenetic regulator and is frequently subject to inactivating mutations across various cancer types. Nevertheless, the precise molecular pathways by which ARID1A deficiency facilitates the progression of HCC remain inadequately elucidated. Methods: RNA sequencing (RNA-seq) was employed to identify genes that were significantly upregulated following the knockdown of ARID1A. Immunohistochemistry was used to assess the expression levels of ARID1A and histone deacetylase 7 (HDAC7) in HCC samples. Chromatin immunoprecipitation and luciferase reporter assays were conducted to validate PU.1 as a positive transcriptional regulator of HDAC7. Protein immunoprecipitation coupled with mass spectrometry was used to identify potential substrates of HDAC7. A xenograft assay was performed to evaluate the therapeutic potential of HDAC7 inhibitors in ARID1A-deficient HCC. Results: Our investigation demonstrated that the loss of ARID1A in HCC cells led to an upregulation of HDAC7 expression. Mechanistic analyses revealed that ARID1A deficiency facilitated PU.1-mediated transcriptional regulation of HDAC7. Additionally, the overexpression of HDAC7 resulted in a reduced acetylation level of Enolase 1 (ENO1), thereby enhancing the malignant proliferation of HCC cells. Targeting HDAC7 effectively inhibited the growth of ARID1A-deficient tumors in tumor-bearing mice. Conclusions: This study provides novel insights into the regulatory interplay between chromatin remodeling and acetylation modification, 2 pivotal epigenetic processes influencing tumorigenesis. It also suggests that pharmacological inhibition of HDAC7 offers a promising therapeutic strategy for treating HCC with ARID1A mutations.


  • Open Access

    Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China

    by Wenjing Zhou, Wulin Shan, Xiaoling Ma, Wenjiao Chang, Xin Zhou, Huaiwei Lu, Yuanyuan Dai

    Background: Staphylococcus aureus (S. aureus) is a major nosocomial pathogen that causes a variety of infections and toxicoses. In recent years, the percentage of rifampicin-resistant S. aureus has increased rapidly in China. The aims of this study were to analyze 1) the level of rifampicin resistance in S. aureus and its correlation with mutations in the rpoB gene, and 2) the molecular characterization of rifampicin-resistant S. aureus isolates. Results: 88 rifampicin-resistant S. aureus isolates were collected for this study. Of the 88 isolates, 83 (94.3%) were high-level rifampicin resistant (MIC≥8 mg/L) while the remaining 5 isolates (5.7%) had a low-level resistance to rifampicin (MIC, 2 to 4 mg/L). Four amino acid substitutions were found in the 88 isolates, which were 481His/Asn (95.5%), 466Leu/Ser (87.5%), 477Ala/Asp (6.8%) and 486Ser/Leu (4.5%) respectively. All mutations were found to be present in cluster I of the rpoB gene. The low-level resistant isolates were found to have only one mutation, while the high-level resistant isolates had at least two or more mutations. The most common multiple mutations were 481His/Asn+466Leu/Ser(92.8%,77/83). The other multiple mutations found were 481His/Asn+477Ala/Asp (6.0%,5/83), and 481His/Asn+466Leu/Ser+477Ala/Asp (1.2%,1/83). Out of 28 high-level rifampicin-resistant S. aureus isolates, three molecular types were found, namely, ST239-MRSA-III-spa t030 (25/28, 89.3%), ST239-MRSA-III-spa t021 (2/28, 7.1%), and ST239-MRSA-III-spa t045 (1/28, 3.6%). Conclusions: Rifampicin resistance in S. aureus was closely associated with mutations in the rpoB gene. High-level rifampicin-resistant S. aureus is one of the most important features in Anhui Provincial Hospital, and high-level rifampicin resistance in S. aureus is associated with multiple mutations of rpoB gene. The prevalence of high-level rifampicin-resistant S. aureus in Anhui may be associated with the spread of the ST239-MRSA III-spa t030 clone.